research use only
Cat.No.S4107
|
In vitro |
DMSO
: 5 mg/mL
(10.56 mM)
Water : Insoluble Ethanol : Insoluble |
|
In vivo |
|||||
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.
| Molecular Weight | 473.4 | Formula | C27H22Cl2N4 |
Storage (From the date of receipt) | |
|---|---|---|---|---|---|
| CAS No. | 2030-63-9 | -- | Storage of Stock Solutions |
|
|
| Synonyms | NSC-141046 | Smiles | CC(C)N=C1C=C2C(=NC3=CC=CC=C3N2C4=CC=C(C=C4)Cl)C=C1NC5=CC=C(C=C5)Cl | ||
| Features |
Intracellular activities of Clofazimine are superior to that of B4154.
|
|---|---|
| Targets/IC50/Ki |
PLA2
|
| In vitro |
Clofazimine stimulates oxygen consumption and superoxide generation by neutrophils, this compound also causes phospholipase A2 activation in neutrophils, resulting in increased release of lysophosphatidylcholine and arachidonic acid from neutrophil membranes. It inhibits mitogen-induced stimulation of peripheral blood mononuclear cells. This chemical stabilizes lysosomal membranes in macrophages and inhibits Mycobacterium leprae metabolism in mouse peritoneal macrophages. It (5 mg/mL) causes dose-related enhancement of the activity of phospholipase A2 in S. aureus, according to an increase in the release of 3H-radiolabeled arachidonate and lysophosphatidylethanolamine ([3H]LPE) from bacterial-membrane phospholipids. This compound inhibits 90% of twenty M. tuberculosis strains with MICs <1.0 μg/mL, to be noted, it inhibits M. tuberculosis strain 2227 with MICs of 0.06 μg/mL. It (1 μg/mL) dose-dependently inhibits activity of J774A.1 macrophages.
|
| In vivo |
Clofazimine (20 mg/kg) prevents mortality and causes a significant reduction in the numbers of CFU in the lungs and spleens of C57BL/6 mice infected M.tuberculosis H37Rv. Liposomal Clofazimine (L-CLF) (50 mg/kg) dose-dependently reduces CFU 2 to 3 log units in the spleen, liver, and lungs of acutely infected mice with Mycobacterium tuberculosis Erdman. This compound (500 μg, bid) results in highest Clofazimine concentrations in spleens and livers of mice whereas Clofazimine concentrations in the lungs are significantly lower. This chemical (20 mg/kg) is effective in reducing bacterial loads in the liver, spleen and lungs of C57BL/6 mice experimentally infected with M. avium strain TMC 724.
|
References |
|
(data from https://clinicaltrials.gov, updated on 2024-05-22)
| NCT Number | Recruitment | Conditions | Sponsor/Collaborators | Start Date | Phases |
|---|---|---|---|---|---|
| NCT05294146 | Completed | Nontuberculous Mycobacterial Diseases |
Radboud University Medical Center |
February 14 2022 | Phase 2 |
| NCT04239326 | Completed | Tuberculosis Multidrug-Resistant |
Foundation for Innovative New Diagnostics Switzerland |
April 16 2021 | -- |
| NCT03341767 | Terminated | Cryptosporidiosis |
University of Washington|Bill and Melinda Gates Foundation|The Emmes Company LLC|Calibr a division of Scripps Research|Liverpool School of Tropical Medicine|University of Virginia|Malawi-Liverpool-Wellcome Trust Clinical Research Programme |
December 14 2017 | Phase 2 |
Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.